Accelerating therapies to patients while managing complexity and cost has become a defining challenge in drug development. BioCina meets this moment with a truly integrated offering — integrating drug substance and drug product capabilities across its Adelaide and Perth facilities. By aligning science, scale, and service under one global framework, the company helps biopharma innovators bring high-quality, cost-effective treatments to market faster and with greater confidence.
Reduced Cost and Greater Control with End-to-End Outsourcing Partners
As drug developers face mounting pressure to accelerate development timelines, they must do so while navigating increasingly complex and diverse pipelines, such as biologics, plasmid DNA (pDNA), and messenger RNA (mRNA)-based therapies. Speed cannot come at the expense of quality, safety, or regulatory compliance. Success depends on finding smarter, more integrated ways of moving from early-phase development to clinical and commercial manufacturing.
One of the most effective strategies is partnering with contract development and manufacturing organizations (CDMOs) that provide true end-to-end capabilities. These integrated partners can manage the full life cycle of drug development, encompassing both drug substance and drug product manufacturing under a single, efficient organizational umbrella. This eliminates the need for costly, time-consuming tech transfers between facilities while also reducing risk and project fragmentation.
Integrated CDMOs streamline supply chains by consolidating activities, such as quality assurance, regulatory support, and project management, under unified governance. Instead of juggling multiple service agreements and quality frameworks across vendors, sponsors benefit from simplified oversight, fewer handoffs, and a single, accountable team. The continuity provided by a dedicated cross-functional team ensures consistent knowledge transfer and avoids delays caused by onboarding new stakeholders at each phase.
Moreover, integrated providers can better anticipate downstream challenges and proactively adjust timelines and capacity needs, minimizing the chance of missed manufacturing slots. In an industry where weeks can make or break market opportunity, this agility is critical. The result is not just speed, but also greater predictability, cost-efficiency, and risk mitigation throughout the drug development journey.
Three Decades of Evolving Capability: Building a Fully Integrated CDMO
BioCina is a global, end-to-end CDMO offering comprehensive services across development, clinical, and commercial manufacturing for biologics and small molecules. Its expertise spans microbial-based therapeutics, pDNA, mRNA, and lipid nanoparticle (LNP) formulations, as well as sterile fill-finish operations for both large and small molecule drug products in a variety of formats.
These capabilities are delivered from two strategically located facilities in Australia: Adelaide and Perth, each with a nearly 30-year legacy of pharmaceutical manufacturing excellence. The Adelaide site was originally spun out of the University of Adelaide’s biochemistry department in the early 1980s and quickly emerged as a hub for microbial biologics innovation. The site’s reputation and technical capabilities drew the attention of Hospira, which acquired it in the early 2000s and expanded its CDMO operations while continuing to advance a growing biologics pipeline.
Pfizer’s acquisition of Hospira in 2015 marked the next chapter, as the global pharma company integrated the Adelaide facility into its broader network. While Pfizer initially paused CDMO operations to concentrate the site’s resources on a single in-house product, that molecule was soon transferred to another manufacturing facility. In 2021, recognizing the site's untapped potential, Pfizer divested the facility to Bridgewest Group, which reestablished the CDMO business under the BioCina brand and invested in expanding capabilities to include pDNA and mRNA.
The Perth site — formerly part of Pfizer’s global sterile injectables network — has a parallel legacy of excellence in aseptic fill-finish manufacturing. In April 2023, Bridgewest Group acquired the Perth facility with the goal of combining it with BioCina’s Adelaide operations to form a true end-to-end CDMO platform. In January 2025, BioCina formally announced the integration of these two sites into a single, unified organization offering seamless support from drug substance to drug product.
Today, the Adelaide site specializes in upstream development and manufacturing for complex biologics, including mRNA and microbial-based products, while the Perth site delivers advanced sterile fill-finish solutions, together creating a full-spectrum CDMO model designed to accelerate innovation across a wide range of modalities.
From Molecule to Market, Without Missing a Beat
The integration of BioCina’s Adelaide and Perth operations has created a unified, end-to-end CDMO platform with a single customer interface. Whether clients require drug substance, drug product, or full-program support, they benefit from harmonized project management, quality systems, documentation standards, and communications processes. This ensures consistency, reduces administrative burden, and delivers a streamlined, transparent experience across all phases of development.
Each client program is assigned a dedicated project manager who serves as a continuous point of contact from early development through final fill-finish. Rather than operating in functional silos, cross-site teams in Adelaide and Perth collaborate closely to align on project timelines, product specifications, and analytical strategy, enabling a continuous flow from initial development through to GMP sterile fill-finish.
Importantly, integration is more than just operational; it’s also technological. BioCina has made targeted investments to ensure each facility can support the other’s evolving client base. The Adelaide site, already equipped with robust capabilities in microbial fermentation and pDNA/mRNA production, is now undergoing expansion to support late-phase and commercial-scale RNA programs, with new RNA manufacturing suites expected online by early 2026. A 2,000-liter fermenter suite will also be installed to support large-scale microbial manufacturing, scheduled to come online in l 2027.
At the Perth facility, originally built for high-volume generic injectables, investments have focused on upgrading infrastructure to support small-batch, high-complexity aseptic fill-finish operations for advanced biologics. This includes flexible lines capable of handling a range of container types and formats, as well as installing a new blow–fill–seal (BFS) line that will significantly expand capacity by May 2026. This new line will replace a previous line with upgraded technology, delivering improved output and flexibility. The recent addition of a state-of-the-art SA25 robotic aseptic filling line further enhances BioCina’s ability to serve niche, early-phase, and high-potency programs, providing clients with the flexibility to scale from clinical to commercial manufacturing without changing partners.
Together, these coordinated upgrades reflect a strategic commitment to integration, not just in branding or systems, but in real, client-facing capability that supports the entire development journey under one roof.
Distinctly Positioned, Technically Equipped, Expertly Led
The seamless integration of BioCina’s Perth and Adelaide facilities is a key differentiator, but it’s only one part of what makes the company distinct in today’s CDMO landscape. BioCina’s strategic location in Australia offers both geographic and regulatory advantages. As a highly developed, English-speaking country positioned between the U.S., EU, and Asia-Pacific regions, Australia enables efficient support for regional and global clinical development and commercialization programs. Unlike emerging markets, Australia offers reliability and predictability, with the added benefit of substantial tax incentives up to 48.5% and government support for clinical trial activity. These advantages are amplified by the country’s strong biopharma infrastructure, intellectual property protections, highly trained workforce, and culture of academic–industry collaboration.
On a technical level, BioCina provides an unusually broad and integrated suite of capabilities across drug substance and drug product. Unlike many microbial-focused CDMOs, BioCina combines deep expertise in microbial fermentation and advanced RNA production with comprehensive fill-finish services, including aseptic filling, BFS technology, and the ability to handle highly potent and cytotoxic substances. This allows the company to support a wide range of product types, from orphan and niche therapies to large-volume biologics, at every phase of the development life cycle.
These technical services are fully supported by in-house analytical development, quality control, regulatory expertise, and global shipping validation, all under a unified quality management system. With facilities licensed by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada and Australia’s Therapeutic Goods Administration (TGA), BioCina is equipped to meet the most stringent global regulatory requirements, offering clients confidence in both compliance and commercial readiness.
Equally important is the team behind these capabilities. BioCina’s experienced professionals have collectively supported hundreds of clinical and commercial programs, delivering products to more than 100 countries worldwide. Many members of the core team have been with the company for decades, with an average tenure of over 15 years across the sites, resulting in deep institutional knowledge, continuity across projects, and consistently high employee retention. That continuity means clients aren’t just engaging with a facility; they’re forming long-term partnerships with a team that will stay with their programs from concept to commercialization.
BioCina’s client-centric approach is evident in every engagement. Programs are tailored to meet each client’s specific needs, with an emphasis on transparent communication, collaborative planning, and proactive problem-solving. These values translate into measurable results: a 95% on-time and in-full (OTIF) delivery rate and meaningful acceleration in time-to-clinic, which contributes to faster ROI and stronger competitive positioning for BioCina’s partners.
Blossoming on the Global Stage
While traditionally conservative, the pharmaceutical industry is now navigating an era of accelerated transformation. Advances in modalities, mechanisms of action, and delivery platforms are unfolding alongside intensifying geopolitical volatility, supply chain vulnerabilities, and rising development costs. In this context, biopharmaceutical companies are under more pressure than ever to reduce risk, compress timelines, and maintain flexibility without compromising quality.
One of the most effective ways to achieve this balance is by partnering with CDMOs that offer truly integrated, end-to-end services across both drug substance and drug product. By consolidating operations under a unified quality, regulatory, and project management system, these partners minimize handoffs, streamline decision-making, and drive predictability throughout the development lifecycle.
BioCina has intentionally built its integrated platform around these priorities. Guided by leadership with decades of experience serving a broad spectrum of pharma and biotech clients, the company has designed its offering to meet the real-world needs of drug developers — not just in terms of technical execution, but also in how programs are managed, communicated, and delivered. The Adelaide and Perth facilities now operate as a single CDMO ecosystem spanning microbial fermentation, pDNA and mRNA development, LNP formulation and encapsulation, and aseptic fill-finish in multiple formats. Major infrastructure investments, such as large-scale RNA capacity in Adelaide and enhanced flexibility for both generics and specialized biologics in Perth, are driven by what BioCina’s team knows matters most to clients: speed, reliability, supply side security and scalable continuity.
As development programs grow more complex and margin for error narrows, BioCina’s strategic integration, operational maturity, and client-centric mindset position it as more than a service provider — it is a long-term partner that helps drug makers de-risk decisions, accelerate milestones, and bring therapies to patients faster.
